Do analysts prefer SCNI or BDRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scinai Immunotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, SCNI or BDRX?

Scinai Immunotherapeutics has higher revenue and earnings than Biodexa Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scinai Immunotherapeutics $1.31M 1.00 -$8.31M -$9.57 N/A Biodexa Pharmaceuticals $470K 12.89 -$8.42M N/A N/A

Is SCNI or BDRX more profitable?

Company Net Margins Return on Equity Return on Assets Scinai Immunotherapeutics N/A N/A N/A Biodexa Pharmaceuticals N/A N/A N/A

Does the media favor SCNI or BDRX?

In the previous week, Scinai Immunotherapeutics and Scinai Immunotherapeutics both had 3 articles in the media. Scinai Immunotherapeutics' average media sentiment score of 0.99 beat Biodexa Pharmaceuticals' score of 0.96 indicating that Scinai Immunotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scinai Immunotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biodexa Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer SCNI or SNGX?

Soligenix has a consensus target price of $6.00, suggesting a potential upside of 1,295.35%. Given Soligenix's stronger consensus rating and higher probable upside, analysts plainly believe Soligenix is more favorable than Scinai Immunotherapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scinai Immunotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Soligenix 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is SCNI or SNGX more profitable?

Scinai Immunotherapeutics' return on equity of 0.00% beat Soligenix's return on equity. Company Net Margins Return on Equity Return on Assets Scinai Immunotherapeutics N/A N/A N/A Soligenix N/A -244.73% -131.22%

Does the media refer more to SCNI or SNGX?

In the previous week, Scinai Immunotherapeutics and Scinai Immunotherapeutics both had 3 articles in the media. Scinai Immunotherapeutics' average media sentiment score of 0.99 beat Soligenix's score of 0.30 indicating that Scinai Immunotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scinai Immunotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Soligenix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer TNFA or SCNI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TNF Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Scinai Immunotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TNFA or SCNI more profitable?

Scinai Immunotherapeutics' return on equity of 0.00% beat TNF Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets TNF Pharmaceuticals N/A -69.21% -33.98% Scinai Immunotherapeutics N/A N/A N/A

Does the media favor TNFA or SCNI?

In the previous week, Scinai Immunotherapeutics had 2 more articles in the media than TNF Pharmaceuticals. MarketBeat recorded 3 mentions for Scinai Immunotherapeutics and 1 mentions for TNF Pharmaceuticals. Scinai Immunotherapeutics' average media sentiment score of 0.99 beat TNF Pharmaceuticals' score of 0.00 indicating that Scinai Immunotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TNF Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Scinai Immunotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate SCNI or GOVX?

GeoVax Labs has a consensus target price of $150.00, suggesting a potential upside of 12,195.08%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts clearly believe GeoVax Labs is more favorable than Scinai Immunotherapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scinai Immunotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is SCNI or GOVX more profitable?

Scinai Immunotherapeutics' return on equity of 0.00% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets Scinai Immunotherapeutics N/A N/A N/A GeoVax Labs N/A -709.52% -399.33%

Does the media refer more to SCNI or GOVX?

In the previous week, Scinai Immunotherapeutics had 1 more articles in the media than GeoVax Labs. MarketBeat recorded 3 mentions for Scinai Immunotherapeutics and 2 mentions for GeoVax Labs. Scinai Immunotherapeutics' average media sentiment score of 0.99 beat GeoVax Labs' score of 0.72 indicating that Scinai Immunotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scinai Immunotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GeoVax Labs 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer APM or SCNI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptorum Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Scinai Immunotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, APM or SCNI?

Aptorum Group has higher earnings, but lower revenue than Scinai Immunotherapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aptorum Group $430K 12.67 -$1.36M N/A N/A Scinai Immunotherapeutics $1.31M 1.00 -$8.31M -$9.57 N/A

Is APM or SCNI more profitable?

Company Net Margins Return on Equity Return on Assets Aptorum Group N/A N/A N/A Scinai Immunotherapeutics N/A N/A N/A

Does the media prefer APM or SCNI?

In the previous week, Aptorum Group had 2 more articles in the media than Scinai Immunotherapeutics. MarketBeat recorded 5 mentions for Aptorum Group and 3 mentions for Scinai Immunotherapeutics. Aptorum Group's average media sentiment score of 1.17 beat Scinai Immunotherapeutics' score of 0.99 indicating that Aptorum Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aptorum Group 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scinai Immunotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Scinai Immunotherapeutics (SCNI) Competitors

$0.33 +0.01 (+1.81%)

Closing price 04:00 PM Eastern

Extended Trading

$0.33 0.00 (-1.21%)

As of 07:51 PM Eastern

Compare

SCNI vs. BDRX, SNGX, TNFA, GOVX, and APM

Should you buy Scinai Immunotherapeutics stock or one of its competitors? MarketBeat compares Scinai Immunotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Scinai Immunotherapeutics include Biodexa Pharmaceuticals (BDRX), Soligenix (SNGX), TNF Pharmaceuticals (TNFA), GeoVax Labs (GOVX), and Aptorum Group (APM). These companies are all part of the "pharmaceutical products" industry.

How does Scinai Immunotherapeutics compare to Biodexa Pharmaceuticals?

Scinai Immunotherapeutics (NASDAQ:SCNI) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

In the previous week, Scinai Immunotherapeutics and Scinai Immunotherapeutics both had 3 articles in the media. Scinai Immunotherapeutics' average media sentiment score of 0.99 beat Biodexa Pharmaceuticals' score of 0.96 indicating that Scinai Immunotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scinai Immunotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biodexa Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

58.4% of Scinai Immunotherapeutics shares are held by institutional investors. Comparatively, 17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. 60.9% of Scinai Immunotherapeutics shares are held by insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scinai Immunotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Scinai Immunotherapeutics	N/A	N/A	N/A
Biodexa Pharmaceuticals	N/A	N/A	N/A

Scinai Immunotherapeutics has higher revenue and earnings than Biodexa Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scinai Immunotherapeutics	$1.31M	1.00	-$8.31M	-$9.57	N/A
Biodexa Pharmaceuticals	$470K	12.89	-$8.42M	N/A	N/A

Scinai Immunotherapeutics has a beta of 2.05, indicating that its share price is 105% more volatile than the broader market. Comparatively, Biodexa Pharmaceuticals has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market.

Summary

Scinai Immunotherapeutics beats Biodexa Pharmaceuticals on 6 of the 7 factors compared between the two stocks.

How does Scinai Immunotherapeutics compare to Soligenix?

Scinai Immunotherapeutics (NASDAQ:SCNI) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

Soligenix has a consensus target price of $6.00, suggesting a potential upside of 1,295.35%. Given Soligenix's stronger consensus rating and higher probable upside, analysts plainly believe Soligenix is more favorable than Scinai Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scinai Immunotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Soligenix	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Scinai Immunotherapeutics and Scinai Immunotherapeutics both had 3 articles in the media. Scinai Immunotherapeutics' average media sentiment score of 0.99 beat Soligenix's score of 0.30 indicating that Scinai Immunotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scinai Immunotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Soligenix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Scinai Immunotherapeutics has higher revenue and earnings than Soligenix. Soligenix is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scinai Immunotherapeutics	$1.31M	1.00	-$8.31M	-$9.57	N/A
Soligenix	$120K	53.11	-$11.08M	-$1.68	N/A

Scinai Immunotherapeutics has a beta of 2.05, meaning that its share price is 105% more volatile than the broader market. Comparatively, Soligenix has a beta of 1.84, meaning that its share price is 84% more volatile than the broader market.

Scinai Immunotherapeutics' return on equity of 0.00% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scinai Immunotherapeutics	N/A	N/A	N/A
Soligenix	N/A	-244.73%	-131.22%

58.4% of Scinai Immunotherapeutics shares are held by institutional investors. Comparatively, 3.6% of Soligenix shares are held by institutional investors. 60.9% of Scinai Immunotherapeutics shares are held by insiders. Comparatively, 3.1% of Soligenix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Scinai Immunotherapeutics beats Soligenix on 9 of the 14 factors compared between the two stocks.

How does Scinai Immunotherapeutics compare to TNF Pharmaceuticals?

TNF Pharmaceuticals (NASDAQ:TNFA) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

9.6% of TNF Pharmaceuticals shares are owned by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. 0.5% of TNF Pharmaceuticals shares are owned by company insiders. Comparatively, 60.9% of Scinai Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Scinai Immunotherapeutics' return on equity of 0.00% beat TNF Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TNF Pharmaceuticals	N/A	-69.21%	-33.98%
Scinai Immunotherapeutics	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TNF Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Scinai Immunotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

TNF Pharmaceuticals has a beta of 2.04, suggesting that its stock price is 104% more volatile than the broader market. Comparatively, Scinai Immunotherapeutics has a beta of 2.05, suggesting that its stock price is 105% more volatile than the broader market.

Scinai Immunotherapeutics has higher revenue and earnings than TNF Pharmaceuticals. Scinai Immunotherapeutics is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TNF Pharmaceuticals	N/A	N/A	-$23.36M	-$231.00	N/A
Scinai Immunotherapeutics	$1.31M	1.00	-$8.31M	-$9.57	N/A

In the previous week, Scinai Immunotherapeutics had 2 more articles in the media than TNF Pharmaceuticals. MarketBeat recorded 3 mentions for Scinai Immunotherapeutics and 1 mentions for TNF Pharmaceuticals. Scinai Immunotherapeutics' average media sentiment score of 0.99 beat TNF Pharmaceuticals' score of 0.00 indicating that Scinai Immunotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TNF Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Scinai Immunotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Scinai Immunotherapeutics beats TNF Pharmaceuticals on 10 of the 11 factors compared between the two stocks.

How does Scinai Immunotherapeutics compare to GeoVax Labs?

Scinai Immunotherapeutics (NASDAQ:SCNI) and GeoVax Labs (NASDAQ:GOVX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation.

GeoVax Labs has a consensus target price of $150.00, suggesting a potential upside of 12,195.08%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts clearly believe GeoVax Labs is more favorable than Scinai Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scinai Immunotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Scinai Immunotherapeutics had 1 more articles in the media than GeoVax Labs. MarketBeat recorded 3 mentions for Scinai Immunotherapeutics and 2 mentions for GeoVax Labs. Scinai Immunotherapeutics' average media sentiment score of 0.99 beat GeoVax Labs' score of 0.72 indicating that Scinai Immunotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scinai Immunotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GeoVax Labs	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are owned by institutional investors. 60.9% of Scinai Immunotherapeutics shares are owned by insiders. Comparatively, 0.7% of GeoVax Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Scinai Immunotherapeutics has higher earnings, but lower revenue than GeoVax Labs. GeoVax Labs is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scinai Immunotherapeutics	$1.31M	1.00	-$8.31M	-$9.57	N/A
GeoVax Labs	$2.49M	1.70	-$21.47M	-$19.12	N/A

Scinai Immunotherapeutics has a beta of 2.05, meaning that its stock price is 105% more volatile than the broader market. Comparatively, GeoVax Labs has a beta of 3.62, meaning that its stock price is 262% more volatile than the broader market.

Scinai Immunotherapeutics' return on equity of 0.00% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scinai Immunotherapeutics	N/A	N/A	N/A
GeoVax Labs	N/A	-709.52%	-399.33%

Summary

Scinai Immunotherapeutics beats GeoVax Labs on 9 of the 14 factors compared between the two stocks.

How does Scinai Immunotherapeutics compare to Aptorum Group?

Aptorum Group (NASDAQ:APM) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

3.8% of Aptorum Group shares are held by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are held by institutional investors. 64.0% of Aptorum Group shares are held by company insiders. Comparatively, 60.9% of Scinai Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Aptorum Group has higher earnings, but lower revenue than Scinai Immunotherapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptorum Group	$430K	12.67	-$1.36M	N/A	N/A
Scinai Immunotherapeutics	$1.31M	1.00	-$8.31M	-$9.57	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptorum Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Scinai Immunotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Aptorum Group	N/A	N/A	N/A
Scinai Immunotherapeutics	N/A	N/A	N/A

In the previous week, Aptorum Group had 2 more articles in the media than Scinai Immunotherapeutics. MarketBeat recorded 5 mentions for Aptorum Group and 3 mentions for Scinai Immunotherapeutics. Aptorum Group's average media sentiment score of 1.17 beat Scinai Immunotherapeutics' score of 0.99 indicating that Aptorum Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aptorum Group	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scinai Immunotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aptorum Group has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market. Comparatively, Scinai Immunotherapeutics has a beta of 2.05, suggesting that its stock price is 105% more volatile than the broader market.

Summary

Aptorum Group beats Scinai Immunotherapeutics on 5 of the 8 factors compared between the two stocks.

Get Scinai Immunotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCNI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SCNI vs. The Competition

Export

Metric	Scinai Immunotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.29M	$3.39B	$6.75B	$12.02B
Dividend Yield	N/A	2.25%	2.66%	5.61%
P/E Ratio	-0.03	10.77	20.34	22.43
Price / Sales	1.00	304.87	510.75	109.73
Price / Cash	N/A	124.89	44.01	55.64
Price / Book	0.42	8.32	10.66	6.79
Net Income	-$8.31M	$23.89M	$3.56B	$337.66M
7 Day Performance	-19.72%	0.94%	0.05%	2.08%
1 Month Performance	-37.90%	-1.16%	0.37%	3.16%
1 Year Performance	-85.79%	41.51%	22.73%	27.78%

Scinai Immunotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SCNI Scinai Immunotherapeutics	1.5256 of 5 stars	$0.33 +1.8%	N/A	-86.3%	$1.29M	$1.31M	N/A	20	Earnings Report High Trading Volume
BDRX Biodexa Pharmaceuticals	1.1035 of 5 stars	$3.43 -4.5%	N/A	-94.5%	$7.17M	$470K	N/A	20	Short Interest Decrease
SNGX Soligenix	2.0071 of 5 stars	$0.48 -0.5%	$6.00 +1,147.7%	-77.2%	$7.16M	$120K	N/A	20	Positive News Short Interest Increase Gap Up
TNFA TNF Pharmaceuticals	0.0212 of 5 stars	$3.85 -6.1%	N/A	-77.4%	$7.11M	N/A	N/A	6
GOVX GeoVax Labs	2.3394 of 5 stars	$1.79 -11.8%	$150.00 +8,279.9%	-95.9%	$7.05M	$2.49M	N/A	10	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SCNI) was last updated on 6/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Scinai Immunotherapeutics (SCNI) Competitors

SCNI vs. BDRX, SNGX, TNFA, GOVX, and APM

How does Scinai Immunotherapeutics compare to Biodexa Pharmaceuticals?

Summary

How does Scinai Immunotherapeutics compare to Soligenix?

Summary

How does Scinai Immunotherapeutics compare to TNF Pharmaceuticals?

Summary

How does Scinai Immunotherapeutics compare to GeoVax Labs?

Summary

How does Scinai Immunotherapeutics compare to Aptorum Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCNI vs. The Competition

Scinai Immunotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Scinai Immunotherapeutics (SCNI) Competitors

SCNI vs. BDRX, SNGX, TNFA, GOVX, and APM

How does Scinai Immunotherapeutics compare to Biodexa Pharmaceuticals?

Does the media favor SCNI or BDRX?

Do institutionals & insiders have more ownership in SCNI or BDRX?

Do analysts prefer SCNI or BDRX?

Is SCNI or BDRX more profitable?

Which has higher valuation & earnings, SCNI or BDRX?

Which has more volatility & risk, SCNI or BDRX?

Summary

How does Scinai Immunotherapeutics compare to Soligenix?

Do analysts prefer SCNI or SNGX?

Does the media refer more to SCNI or SNGX?

Which has better valuation and earnings, SCNI or SNGX?

Which has more volatility & risk, SCNI or SNGX?

Is SCNI or SNGX more profitable?

Do institutionals & insiders have more ownership in SCNI or SNGX?

Summary

How does Scinai Immunotherapeutics compare to TNF Pharmaceuticals?

Do institutionals and insiders have more ownership in TNFA or SCNI?

Is TNFA or SCNI more profitable?

Do analysts prefer TNFA or SCNI?

Which has more volatility and risk, TNFA or SCNI?

Which has stronger valuation and earnings, TNFA or SCNI?

Does the media favor TNFA or SCNI?

Summary

How does Scinai Immunotherapeutics compare to GeoVax Labs?

Do analysts rate SCNI or GOVX?

Does the media refer more to SCNI or GOVX?

Do insiders and institutionals have more ownership in SCNI or GOVX?

Which has preferable earnings and valuation, SCNI or GOVX?

Which has more volatility and risk, SCNI or GOVX?

Is SCNI or GOVX more profitable?

Summary

How does Scinai Immunotherapeutics compare to Aptorum Group?

Do institutionals and insiders have more ownership in APM or SCNI?

Which has higher valuation and earnings, APM or SCNI?

Do analysts prefer APM or SCNI?

Is APM or SCNI more profitable?

Does the media prefer APM or SCNI?

Which has more risk & volatility, APM or SCNI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCNI vs. The Competition

Scinai Immunotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools